Clinical Trial Update: Expanded Access to Vodobatinib for Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Not Responded to Previous Treatments

View source ↗

Summary

Expanded access update for vodobatinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia who have not responded to prior treatments.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Vodobatinib (Vodobatinib)

Snippet

Sponsor: Sun Pharma Advanced Research Company Limited | Conditions: CML, Relapsed, CML, Refractory | Status: TEMPORARILY_NOT_AVAILABLE